Pregnancy (rhesus negative women) - routine anti-D (review)
Routine antenatal anti-D prophylaxis for women who are rhesus D negative (TA156)
1. Guidance
NOTE: This guidance replaces ‘NICE technology appraisal guidance 41’ issued in May 2002.
The Institute reviews each piece of guidance it issues. This review and reappraisal of routine antenatal anti-D prophylaxis (RAADP) for women who are rhesus D (RhD) negative has resulted in no change to the recommendations regarding which women are eligible for RAADP and the indications for its use. This review has appraised preparations that can be administered as single-dose or two-dose regimens, and recommends that the preparation with the lowest associated cost should be used.
1.1. Routine antenatal anti-D prophylaxis (RAADP) is recommended as a treatment option for all pregnant women who are rhesus D (RhD) negative and who are not known to be sensitised to the RhD antigen.
1.2. When a decision has been made to give RAADP, the preparation with the lowest associated cost should be used. This cost should take into account the lowest acquisition cost available locally and costs associated with administration.
